Lv1
29 积分 2021-07-21 加入
Reliability of Hepatic Steatosis Quantification by Controlled Attenuation Parameter in Steatotic Liver Disease
4小时前
求助中
Effectiveness of a non-physician community health-care provider-led intensive blood pressure intervention versus usual care on cardiovascular disease (CRHCP): an open-label, blinded-endpoint, cluster-randomised trial
10小时前
已完结
A village doctor-led multifaceted intervention for blood pressure control in rural China: an open, cluster randomised trial
10小时前
已完结
Reliability of Hepatic Steatosis Quantification by Controlled Attenuation Parameter in Steatotic Liver Disease
2天前
求助中
Cardiovascular outcomes of GLP-1RA vs SGLT2i in MASLD and type 2 diabetes: real-world evidence
2天前
求助中
Non-invasive risk scores for prediction of type 2 diabetes (EPIC-InterAct): a validation of existing models
5天前
已关闭
The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis
6天前
已完结
Implementing sustainable liver health in Europe: a second EASL–Lancet Commission
6天前
已完结
Efficacy and safety of ervogastat alone and in combination with clesacostat in patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis and F2–F3 fibrosis (MIRNA): results from a phase 2, randomised, double-blind, double-dummy study
6天前
已完结
Global burden of metabolic dysfunction-associated steatotic liver disease, 1990–2023, and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2023
6天前
已完结
皖公网安备34019202002308
